Dialysis provider DaVita Inc. (NYSE:DVA) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 9.9% year on year to $3.62 billion. Its non-GAAP profit of $3.40 per share was 6.5% above analysts’ consensus estimates.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only realized strong financial performance but also propelled the broader industry’s returns
as healthcare stocks have gained 17.4% over the past six months while the S&P 500 was up 9.6%.
Date: January 28, 2026 The landscape of American managed care is currently undergoing a seismic shift, and perhaps no company exemplifies this transformation—and the accompanying volatility—more than Humana Inc. (NYSE: HUM). Long considered the "pure-play" leader in Medicare Advantage (MA), Humana finds itself at a critical juncture. As of today, January 28, 2026, the company [...]
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns.
Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor.
The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Curious about the market action on Wednesday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
As the final trading days of 2025 unfold, the traditional "Santa Claus Rally" is being reshaped by a wave of aggressive 2026 price target revisions from Wall Street’s most influential institutions. With the S&P 500 hovering near historic highs, investors are less concerned with the closing tallies of
As the final weeks of 2025 draw to a close, the global financial landscape is entering a pivotal transformation. The "AI Gold Rush" that defined the previous two years is evolving from a speculative frenzy into a disciplined era of monetization and operational efficiency. Simultaneously, a unique confluence of fiscal
Warren Buffett's Berkshire Hathaway has once again sent ripples through the financial markets with its latest Q3 2025 13F filing, released on November 14, 2025. The filing revealed a continuation of the conglomerate's cautious stance, marking a twelfth consecutive quarter of net stock sales and an unprecedented accumulation of cash,
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings.
However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated he sees “room for a further adjustment” in the near term, sparking a significant market rally. Following his remarks, the probability of the central bank cutting rates at its December meeting jumped from 39% to over 73%, according to the CME FedWatch tool. This positive sentiment provided relief to markets amid concerns over high valuations, particularly in AI-related stocks.
In a move that has sent ripples across the financial world, Berkshire Hathaway, the venerable conglomerate led by Warren Buffett, has disclosed a significant new stake in Alphabet (NASDAQ: GOOGL), the parent company of Google. This revelation, made in a regulatory filing on Friday, November 14, 2025, detailing Berkshire's equity
Let’s dig into the relative performance of DaVita (NYSE:DVA) and its peers as we unravel the now-completed Q3 outpatient & specialty care earnings season.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
